155 related articles for article (PubMed ID: 37691032)
1. EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.
Alzate JD; Mullen R; Mashiach E; Bernstein K; De Nigris Vasconcellos F; Rotmann L; Berger A; Qu T; Silverman JS; Golfinos JG; Donahue BR; Kondziolka D
J Neurooncol; 2023 Sep; 164(2):387-396. PubMed ID: 37691032
[TBL] [Abstract][Full Text] [Related]
2. Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC).
Shuto T; Akabane A; Yamamoto M; Serizawa T; Higuchi Y; Sato Y; Kawagishi J; Yamanaka K; Jokura H; Yomo S; Nagano O; Aoyama H
J Neurosurg; 2018 Dec; 129(Suppl1):86-94. PubMed ID: 30544291
[TBL] [Abstract][Full Text] [Related]
3. Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery.
Johnson MD; Avkshtol V; Baschnagel AM; Meyer K; Ye H; Grills IS; Chen PY; Maitz A; Olson RE; Pieper DR; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):537-43. PubMed ID: 26867883
[TBL] [Abstract][Full Text] [Related]
4. Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases.
Minniti G; Lanzetta G; Capone L; Giraffa M; Russo I; Cicone F; Bozzao A; Alongi F; Nicosia L; Fineschi G; Marchetti L; Tufo T; Bianciardi F; Esposito V; Gentile P; Paolini S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949695
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases.
Wolf A; Donahue B; Silverman JS; Chachoua A; Lee JK; Kondziolka D
J Neurooncol; 2017 Aug; 134(1):139-143. PubMed ID: 28536993
[TBL] [Abstract][Full Text] [Related]
6. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery.
Siomin VE; Vogelbaum MA; Kanner AA; Lee SY; Suh JH; Barnett GH
J Neurooncol; 2004; 67(1-2):115-21. PubMed ID: 15072456
[TBL] [Abstract][Full Text] [Related]
7. Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer.
Trifiletti DM; Romano KD; Xu Z; Reardon KA; Sheehan J
J Neurooncol; 2015 Sep; 124(3):421-7. PubMed ID: 26093620
[TBL] [Abstract][Full Text] [Related]
8. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases.
Atalar B; Modlin LA; Choi CY; Adler JR; Gibbs IC; Chang SD; Harsh GR; Li G; Nagpal S; Hanlon A; Soltys SG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):713-8. PubMed ID: 24054875
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.
Huang AJ; Huang KE; Page BR; Ayala-Peacock DN; Lucas JT; Lesser GJ; Laxton AW; Tatter SB; Chan MD
J Neurooncol; 2014 Oct; 120(1):163-9. PubMed ID: 25048529
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
[TBL] [Abstract][Full Text] [Related]
12. Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery.
Teyateeti A; Brown PD; Mahajan A; Laack NN; Pollock BE
Neurooncol Adv; 2021; 3(1):vdab036. PubMed ID: 33860228
[TBL] [Abstract][Full Text] [Related]
13. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
14. Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
Li Y; Liu B; Connolly ID; Kakusa BW; Pan W; Nagpal S; Montgomery SB; Hayden Gephart M
J Thorac Oncol; 2018 Jul; 13(7):1022-1027. PubMed ID: 29604399
[TBL] [Abstract][Full Text] [Related]
15. A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases.
Prabhu RS; Turner BE; Asher AL; Marcrom SR; Fiveash JB; Foreman PM; Press RH; Patel KR; Curran WJ; Breen WG; Brown PD; Jethwa KR; Grills IS; Arden JD; Foster LM; Manning MA; Stern JD; Soltys SG; Burri SH
Neuro Oncol; 2019 Aug; 21(8):1049-1059. PubMed ID: 30828727
[TBL] [Abstract][Full Text] [Related]
16. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
Tatineni V; O'Shea PJ; Ozair A; Khosla AA; Saxena S; Rauf Y; Jia X; Murphy ES; Chao ST; Suh JH; Peereboom DM; Ahluwalia MS
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190312
[No Abstract] [Full Text] [Related]
17. Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.
Brown DA; Lu VM; Himes BT; Burns TC; Quiñones-Hinojosa A; Chaichana KL; Parney IF
Clin Exp Metastasis; 2020 Apr; 37(2):341-352. PubMed ID: 31950392
[TBL] [Abstract][Full Text] [Related]
18. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
19. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
Yomo S; Oda K
Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
[TBL] [Abstract][Full Text] [Related]
20. The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.
Cheng WC; Shen YC; Chien CR; Liao WC; Chen CH; Hsia TC; Tu CY; Chen HJ
Thorac Cancer; 2022 May; 13(10):1505-1512. PubMed ID: 35394114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
